Jamjoom Pharmaceuticals Factory Co. (Jamjoom Pharma) reported a net profit of SAR 209.9 million in H1 2024, an increase of 23% from SAR 170.7 million in the year-earlier period.
| Item | 6m 2023 | 6m 2024 | Change |
|---|---|---|---|
| Revenues | 599.25 | 731.20 | 22.0 % |
| Gross Income | 397.70 | 467.59 | 17.6 % |
| Operating Income | 186.47 | 230.84 | 23.8 % |
| Net Income | 170.67 | 209.92 | 23.0 % |
| Average Shares | 70.00 | 70.00 | - |
| EPS (Riyals) | 2.44 | 3.00 | 23.0 % |
The company cited higher revenue, offset by cost of sales, but was further improved through cost efficiencies in other operating expenses, and other income.
| Item | Q2 2023 | Q2 2024 | Change |
|---|---|---|---|
| Revenues | 298.40 | 345.74 | 15.9 % |
| Gross Income | 198.10 | 218.18 | 10.1 % |
| Operating Income | 92.56 | 104.26 | 12.6 % |
| Net Income | 86.27 | 106.95 | 24.0 % |
| Average Shares | 70.00 | 70.00 | - |
| EPS (Riyals) | 1.23 | 1.53 | 24.0 % |
| Item | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Revenues | 385.46 | 345.74 | (10.3 %) |
| Gross Income | 249.40 | 218.18 | (12.5 %) |
| Operating Income | 126.58 | 104.26 | (17.6 %) |
| Net Income | 102.97 | 106.95 | 3.9 % |
| Average Shares | 70.00 | 70.00 | - |
| EPS (Riyals) | 1.47 | 1.53 | 3.9 % |
Q2 2024 net profit reached SAR 107 million, up 24% from SAR 86.2 million in the year-earlier period, spurred by revenue growth, improved cost management and efficiency, as well as other income.
On a quarterly basis, Q2 2024 net earnings grew 3.9% from SAR 102.9 million in Q1 2024.
Total shareholders’ equity (no minority interest) reached SAR 1.46 billion by June 30, 2024, compared to SAR 1.35 billion in the corresponding period of the year before.
| Company | Estimated | Actual | Change |
|---|---|---|---|
| SAUDI ARAMCO | 104,019.94 | 106,158.00 | 2.1 % |
| SAUDI CEMENT | 90.58 | 87.30 | (3.6 %) |
| DAR ALARKAN | 173.60 | 165.12 | (4.9 %) |
| LUMI | 54.61 | 46.01 | (15.8 %) |
| SPCC | 45.14 | 30.00 | (33.5 %) |
| SAVOLA GROUP | 258.90 | 135.39 | (47.7 %) |
| Company | Estimated | Actual | Change |
|---|---|---|---|
| ALAMAR | 11.00 | 13.05 | 18.6 % |
| SAUDI ARAMCO | 104,019.94 | 106,158.00 | 2.1 % |
| JAMJOOM PHARMA | 106.61 | 106.95 | 0.3 % |
| Company | Estimated | Actual | Change |
|---|---|---|---|
| SAVOLA GROUP | 258.90 | 135.39 | (47.7 %) |
| SPCC | 45.14 | 30.00 | (33.5 %) |
| A.OTHAIM MARKET | 58.76 | 43.28 | (26.3 %) |
| LUMI | 54.61 | 46.01 | (15.8 %) |
| YSCC | 98.89 | 84.62 | (14.4 %) |
| DAR ALARKAN | 173.60 | 165.12 | (4.9 %) |
| SAUDI CEMENT | 90.58 | 87.30 | (3.6 %) |
Argaam Investment Company has updated the Privacy Policy of its services and digital platforms. Know more about our Privacy Policy here.
Argaam uses cookies to personalize content, to provide social media features and analyze traffic, that we might also share with third parties. You consent to our cookies if you use this website
Comments {{getCommentCount()}}
Be the first to comment
رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}
{{comment.DisplayName}}
{{comment.ElapsedTime}}